Home › Free Stock Grades › ACAD
ACADIA Pharmaceuticals Inc. (ACAD) Stock Grade
ACAD · Healthcare
A+
Market Cap
$4.5B
P/E Ratio
11.6
Revenue Growth (YoY)
+11.9%
Net Margin
36.5%
Return on Equity
31.9%
Dividend Yield
None
About ACADIA Pharmaceuticals Inc.'s fundamentals
ACADIA Pharmaceuticals is a $4.5 billion market-cap biotechnology company with a P/E ratio of 11.6, suggesting relatively modest valuation relative to earnings. The company demonstrates strong operational performance, with year-over-year revenue growth of 11.9%, a net profit margin of 36.5%, and a return on equity of 31.9%, indicating efficient conversion of revenue to profit and effective use of shareholder capital. ACADIA does not currently pay a dividend, which is typical for growth-oriented biotechnology firms that prioritize reinvestment.